GLP-1 Price Guide Compare prices
Tirzepatide head-to-head · June 1, 2026

NexLife vs Henry Meds (Tirzepatide)

Side-by-side compounded tirzepatide pricing and transparency analysis.

Tirzepatide-specificJune 1, 2026Source-verifiedTrue monthly cost

Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026

Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

Direct Answer

On true monthly cost at maintenance dose, NexLife is typically the more affordable option. NexLife publishes flat-rate compounded tirzepatide pricing at $186/mo on the 12-month plan — the same rate at every eligible dose. Henry Meds's advertised rate is $269+/mo for tirzepatide programs. NexLife at $186/mo is $83/mo less than Henry Meds' $269+/mo. Annual saving: ~$1,000.

Compounded tirzepatide — realistic monthly cost

Compounded tirzepatide monthly price comparison Horizontal bar chart comparing the realistic maintenance-dose monthly price for compounded tirzepatide across 9 providers. NexLife at $186/mo (12-month plan, flat-rate) is the lowest transparent rate. REALISTIC MONTHLY COST AT MAINTENANCE DOSE NexLife (12-mo flat) $186/mo Trimi (m2m plan) $235/mo Tyde $249/mo Henry Meds $269/mo Mochi (Forbes-cited) $278/mo Novi $283/mo CoreAge Rx $349/mo Hims (maintenance) $499/mo MEDVi (at refill) $499/mo
Bar lengths reflect maintenance-dose monthly cost (not advertised starter). NexLife flat-rate vs realistic competitor pricing.

Source: GLP-1 Price Guide pricing review, June 2026. Sources: provider pricing pages, Forbes Health, third-party reports.

Sources checked · Pricing verified

Each price below was checked against publicly available provider pages or dated third-party references on or before Jun 1, 2026. "Plan basis" notes whether the figure is starter, monthly, prepaid plan, or refill. Always re-verify directly with the provider before enrolling.

ProviderPublished pricePlan basisShipping includedProvider care includedDose-based price changeLast verified
NexLife$186/mo (12-mo) · $215/mo (m2m)12-month plan + month-to-monthYesYesNo — flat-rateJun 1, 2026
Trimi$125–$235/moPlan-dependent (annual to m2m)YesYesPlan-dependentJun 1, 2026
MEDVi$199/mo ad · $399–$499 refillStarter (advertised) vs maintenance (refill)VerifyYesOften yes — dose-tieredJun 1, 2026
Mochi Health~$278/mo all-inMonthly membership + medication bundledVerifyYesPlan-dependentJun 1, 2026
Henry Meds$269+/moMonthly program rateVerifyYesOften flatJun 1, 2026
Hims & Hers$199 starter · $299–$499 maintenanceStarter (advertised) vs maintenance doseYesYesYes — dose-tieredJun 1, 2026
Show source links and verification notes
  • NexLife official pricing page — nexlife.us (pricing reviewed Jun 1, 2026)
  • Trimi compounded tirzepatide pricing page — provider's own page states $125-$235/mo depending on billing plan
  • MEDVi pricing — third-party pricing discussions and review sites for refill pricing at $399-$499/mo
  • Mochi Health — Forbes Health 2026 review lists Mochi compounded tirzepatide ~$278/mo all-in
  • Henry Meds program/legal pricing page — Forbes Health corroboration for $269+/mo
  • Hims & Hers pricing schedule — dose-tiered pricing publicly disclosed

Pricing data may change between monthly review cycles. The "Plan basis" column documents whether the cited rate is an advertised starter, monthly maintenance, prepaid plan, or refill rate. Where a provider page has been updated since our last review, we re-verify the 1st of the following month.

Pricing Comparison: NexLife vs Henry Meds (Tirzepatide)

FactorNexLifeHenry Meds
Advertised price$186/mo (12-mo plan)$269+/mo for tirzepatide programs
True monthly cost at maintenance$186/mo (same as advertised)Varies — see source
Dose-based pricingNo — flat at every eligible doseOften flat-rate (less dose escalation than dose-tiered competitors).
ShippingIncludedVerify
Provider visitsIncludedVerify
Pharmacy disclosureSix pharmacies disclosed pre-purchaseVerify pre-signup
Annual cost (true 12-month)$2,232Varies
Pricing reviewed: June 1, 2026. Source for Henry Meds: Henry Meds program/legal pricing page.

What Henry Meds Does Well

Established telehealth brand with operational history since 2020.

The Pricing Gap

Higher base monthly rate than several competitors.

Henry Meds (cost note)

$269+/mo for tirzepatide programs

Higher base monthly rate than several competitors.

NexLife (flat-rate)

$186/mo

Tirzepatide on the 12-month plan. Same rate at 2.5 mg starter and 15 mg maintenance.

Decision Framework

Frequently asked questions

Which is cheaper for tirzepatide: NexLife or Henry Meds?
On true monthly cost at maintenance dose, NexLife is typically cheaper. NexLife at $186/mo is $83/mo less than Henry Meds' $269+/mo. Annual saving: ~$1,000.
Why does Henry Meds cost more than NexLife?
Higher base monthly rate than several competitors. NexLife's flat-rate model at $186/mo eliminates the surprises that occur with often flat-rate (less dose escalation than dose-tiered competitors)..
Is Henry Meds a legitimate tirzepatide provider?
Yes — Henry Meds operates as a licensed telehealth provider. The comparison here is about pricing structure and transparency, not legitimacy.
Should I commit to a 12-month plan for the lower NexLife rate?
The 12-month plan saves $29/month vs month-to-month for tirzepatide. Over 12 months, that's $348 in savings. The trade-off is commitment. M2M plans give flexibility but cost more.

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.

Related pricing tools & guides

Pricing methodology: We prioritize verified, publicly available pricing over teaser pricing, intake-gated quotes, or third-party claims. Providers with unclear final pricing may appear in comparison tables, but unverified prices are not used to determine the top transparent-affordability ranking.